Literature DB >> 24754000

Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue.

Seth Love1, Katy Chalmers1, Paul Ince2, Margaret Esiri3, Johannes Attems4, Kurt Jellinger5, Masahito Yamada6, Mark McCarron7, Thais Minett8, Fiona Matthews9, Steven Greenberg10, David Mann11, Patrick Gavin Kehoe1.   

Abstract

In a collaboration involving 11 groups with research interests in cerebral amyloid angiopathy (CAA), we used a two-stage process to develop and in turn validate a new consensus protocol and scoring scheme for the assessment of CAA and associated vasculopathic abnormalities in post-mortem brain tissue. Stage one used an iterative Delphi-style survey to develop the consensus protocol. The resultant scoring scheme was tested on a series of digital images and paraffin sections that were circulated blind to a number of scorers. The scoring scheme and choice of staining methods were refined by open-forum discussion. The agreed protocol scored parenchymal and meningeal CAA on a 0-3 scale, capillary CAA as present/absent and vasculopathy on 0-2 scale, in the 4 cortical lobes that were scored separately. A further assessment involving three centres was then undertaken. Neuropathologists in three centres (Bristol, Oxford and Sheffield) independently scored sections from 75 cases (25 from each centre) and high inter-rater reliability was demonstrated. Stage two used the results of the three-centre assessment to validate the protocol by investigating previously described associations between APOE genotype (previously determined), and both CAA and vasculopathy. Association of capillary CAA with or without arteriolar CAA with APOE ε4 was confirmed. However APOE ε2 was also found to be a strong risk factor for the development of CAA, not only in AD but also in elderly non-demented controls. Further validation of this protocol and scoring scheme is encouraged, to aid its wider adoption to facilitate collaborative and replication studies of CAA.

Entities:  

Keywords:  APOE; Angiopathy; CAA; Delphi; amyloid; consensus; dementia; meningeal; parenchymal; validation

Year:  2014        PMID: 24754000      PMCID: PMC3986608     

Source DB:  PubMed          Journal:  Am J Neurodegener Dis        ISSN: 2165-591X


  37 in total

1.  The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant.

Authors:  J M Olichney; L A Hansen; D Galasko; T Saitoh; C R Hofstetter; R Katzman; L J Thal
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

2.  Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan.

Authors:  J Masuda; K Tanaka; K Ueda; T Omae
Journal:  Stroke       Date:  1988-02       Impact factor: 7.914

3.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

4.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

5.  Two types of sporadic cerebral amyloid angiopathy.

Authors:  Dietmar Rudolf Thal; Estifanos Ghebremedhin; Udo Rüb; Haruyasu Yamaguchi; Kelly Del Tredici; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

6.  Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study.

Authors:  J P Vonsattel; R H Myers; E T Hedley-Whyte; A H Ropper; E D Bird; E P Richardson
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

7.  APOE and cerebral amyloid angiopathy in the elderly.

Authors:  Seth Love; James A R Nicoll; Anthony Hughes; Gordon K Wilcock
Journal:  Neuroreport       Date:  2003-08-06       Impact factor: 1.837

8.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Authors:  D E Schmechel; A M Saunders; W J Strittmatter; B J Crain; C M Hulette; S H Joo; M A Pericak-Vance; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

9.  Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.

Authors:  S M Greenberg; G W Rebeck; J P Vonsattel; T Gomez-Isla; B T Hyman
Journal:  Ann Neurol       Date:  1995-08       Impact factor: 10.422

10.  APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis.

Authors:  Kristiina Rannikmäe; Rajesh N Kalaria; Steven M Greenberg; Helena C Chui; Frederick A Schmitt; Neshika Samarasekera; Rustam Al-Shahi Salman; Cathie L M Sudlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-10-25       Impact factor: 10.154

View more
  74 in total

1.  Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes.

Authors:  Jonathan Graff-Radford; Timothy G Lesnick; Michelle M Mielke; Eleni Constantopoulos; Alejandro A Rabinstein; Scott A Przybelski; Prashanthi Vemuri; Hugo Botha; David T Jones; Vijay K Ramanan; Ronald C Petersen; David S Knopman; Bradley F Boeve; Melissa E Murray; Dennis W Dickson; Clifford R Jack; Kejal Kantarci; R Ross Reichard
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 2.  The vascular basement membrane in the healthy and pathological brain.

Authors:  Maj S Thomsen; Lisa J Routhe; Torben Moos
Journal:  J Cereb Blood Flow Metab       Date:  2017-07-28       Impact factor: 6.200

Review 3.  Emerging concepts in sporadic cerebral amyloid angiopathy.

Authors:  Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

4.  A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology.

Authors:  Michael L Alosco; Michael A Sugarman; Lilah M Besser; Yorghos Tripodis; Brett Martin; Joseph N Palmisano; Neil W Kowall; Rhoda Au; Jesse Mez; Charles DeCarli; Thor D Stein; Ann C McKee; Ronald J Killiany; Robert A Stern
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 5.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

6.  Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy.

Authors:  Annemieke Ter Telgte; Ashley A Scherlek; Yael D Reijmer; Andre J van der Kouwe; Thijs van Harten; Marco Duering; Brian J Bacskai; Frank-Erik de Leeuw; Matthew P Frosch; Steven M Greenberg; Susanne J van Veluw
Journal:  Acta Neuropathol       Date:  2020-02-27       Impact factor: 17.088

7.  Application of the condensed protocol for the NIA-AA guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice.

Authors:  Rajnish Bharadwaj; Patrick J Cimino; Margaret E Flanagan; Caitlin S Latimer; Luis F Gonzalez-Cuyar; Gordana Juric-Sekhar; Thomas J Montine; Desiree A Marshall; C Dirk Keene
Journal:  Histopathology       Date:  2017-11-22       Impact factor: 5.087

8.  Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-29       Impact factor: 3.575

Review 9.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.